Processing

Please wait...

Settings

Settings

1. WO2003074024 - FORMOTEROL SUPERFINE FORMULATION

Publication Number WO/2003/074024
Publication Date 12.09.2003
International Application No. PCT/EP2003/001964
International Filing Date 26.02.2003
Chapter 2 Demand Filed 23.09.2003
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4704
2-Quinolinones, e.g. carbostyril
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
485
Morphinan derivatives, e.g. morphine, codeine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
08
containing oxygen
10
Alcohols; Phenols; Salts thereof
A61K 31/00 (2006.01)
A61K 31/4704 (2006.01)
A61K 31/485 (2006.01)
A61K 45/06 (2006.01)
A61K 47/10 (2006.01)
CPC
A61K 31/167
A61K 31/4704
A61K 31/485
A61K 45/06
A61K 47/10
A61K 9/008
Applicants
  • CHIESI FARMACEUTICI S.P.A [IT/IT]; Via Palermo 26/A I-43100 Parma, IT (AllExceptUS)
  • DAVIES, Rebecca, Jaine [GB/IT]; IT (UsOnly)
  • GANDERTON, David [GB/IT]; IT (UsOnly)
  • LEWIS, David, Andrew [GB/IT]; IT (UsOnly)
  • MEAKIN, Brian, John [GB/IT]; IT (UsOnly)
  • CHURCH, Tanya, Kathleen [GB/IT]; IT (UsOnly)
  • BRAMBILLA, Gaetano [IT/IT]; IT (UsOnly)
  • FERRARIS, Alessandra [IT/IT]; IT (UsOnly)
Inventors
  • DAVIES, Rebecca, Jaine; IT
  • GANDERTON, David; IT
  • LEWIS, David, Andrew; IT
  • MEAKIN, Brian, John; IT
  • CHURCH, Tanya, Kathleen; IT
  • BRAMBILLA, Gaetano; IT
  • FERRARIS, Alessandra; IT
Agents
  • MINOJA, Fabrizio ; Bianchetti Bracco Minoja S.r.l. Via Rossini, 8 I-20122 Milano, IT
Priority Data
02004786.601.03.2002EP
02023589.123.10.2002EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FORMOTEROL SUPERFINE FORMULATION
(FR) PREPARATION SUPERFINE DE FORMOTEROL
Abstract
(EN)
The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting ß2-agonist by inhalation. In particular this invention relates to a chemically stable highly efficient formoterol HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
(FR)
La présente invention concerne une préparation pharmaceutique destinée à l'administration d'un agoniste $g(b)2 à action prolongée par inhalation. Plus particulièrement, cette invention concerne une préparation de solution HFA de formotérol hautement efficace et chimiquement stable destinée à être administrée au moyen d'aérosols-doseurs pressurisés (PMDI) caractérisés par une pénétration pulmonaire profonde. L'invention se rapporte en outre à des procédés de fabrication de cette préparation, ainsi qu'à son utilisation pour traiter des maladies respiratoires telles que l'asthme et la bronchopneumopathie chronique obstructive (BPCO).
Also published as
GE8391
GE8391/1
HRP20040752A
IN2501/DELNP/2004
NO20043626
NZ535018
PH1-2004-501299
PH12004501299
PL372173
PLP.372173
RSP-767/04
YUP-767/04
ZA200406919
Latest bibliographic data on file with the International Bureau